Ignite Creation Date:
2024-05-06 @ 4:08 PM
Last Modification Date:
2024-10-26 @ 2:04 PM
Study NCT ID:
NCT04889768
Status:
NOT_YET_RECRUITING
Last Update Posted:
2021-05-17
First Post:
2021-05-12
Brief Title:
HIPEC Combined With Camrelizumab Paclitaxel and S-1 for Conversion Therapy in Patients With Advanced Gastric Cancer With Peritoneal Metastasis
Sponsor:
Zhejiang Cancer Hospital
Organization:
Zhejiang Cancer Hospital
Study Overview
Official Title:
HIPEC Combined With Camrelizumab Paclitaxel and S-1 for Conversion Therapy in Patients With Advanced Gastric Cancer With Peritoneal Metastasis
Status:
NOT_YET_RECRUITING
Status Verified Date:
2021-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
There is no currently available treatment for peritoneal metastasis of gastric cancer Hyperthermic intraperitoneal chemotherapy HIPEC can not only maintain the high concentration of drugs in the abdominal cavity but also improve the anti-tumor efficacy of chemotherapy drugs through the thermo-thermal effect In recent years immunotherapy has made great progress in the treatment of gastric cancer We want to explore the hyperthermic intraperitoneal chemotherapy HIPEC combined with Camrelizumab SHR-1210 and intravenous chemotherapy for Creating the Operation Chance in advanced gastric cancer with peritoneal metastasis
Detailed Description:
To assess the effectiveness and safety of Hyperthermic intraperitoneal chemotherapy anti-PD-1 antibody Camrelizumab SHR-1210 intravenous chemotherapy combined with surgery for the treatment of advanced gastric cancer with peritoneal metastasis so as to further find out the optimal protocol for the Conversion therapy in the patients with advanced gastric cancer
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None